Iridian Asset Management’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,448,662
| Closed | -$123M | – | 92 |
|
|
2019
Q4 | $123M | Sell |
1,448,662
-1,552,700
| -52% | -$104M | 2.02% | 24 |
|
|
2019
Q3 | $150M | Sell |
3,001,362
-452,657
| -13% | -$18.1M | 2.35% | 19 |
|
|
2019
Q2 | $126M | Sell |
3,454,019
-363,525
| -10% | -$11.9M | 1.82% | 29 |
|
|
2019
Q1 | $107M | Buy |
3,817,544
+520,728
| +16% | +$12.3M | 1.36% | 40 |
|
|
2018
Q4 | $63.1M | Buy |
3,296,816
+1,417,229
| +75% | +$33M | 0.85% | 43 |
|
|
2018
Q3 | $56.2M | Sell |
1,879,587
-224,652
| -11% | -$8.46M | 0.56% | 47 |
|
|
2018
Q2 | $77.2M | Sell |
2,104,239
-54,694
| -3% | -$1.78M | 0.71% | 49 |
|
|
2018
Q1 | $71.1M | Sell |
2,158,933
-11,282
| -0.5% | -$353K | 0.64% | 52 |
|
|
2017
Q4 | $59.3M | Buy |
2,170,215
+408,177
| +23% | +$12.6M | 0.5% | 49 |
|
|
2017
Q3 | $65.3M | Sell |
1,762,038
-1,915,708
| -52% | -$70.6M | 0.56% | 51 |
|
|
2017
Q2 | $140M | Buy |
3,677,746
+655,065
| +22% | +$29.2M | 1.24% | 43 |
|
|
2017
Q1 | $148M | Buy |
3,022,681
+2,074,261
| +219% | +$94.6M | 1.33% | 38 |
|
|
2016
Q4 | $32.2M | Buy |
+948,420
| New | +$33.6M | 0.3% | 52 |
|
Other funds holding MDCO
Iridian Asset Management's MDCO Position: Q1 2020 in Review
Iridian Asset Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 1,448,662 shares — an estimated $123M sold.
Iridian Asset Management first reported a position in MDCO in Q4 2016 and held it in 13 quarters. The position peaked at $150M in Q3 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Iridian Asset Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Iridian Asset Management sold 1,448,662 Medicines Co shares in Q1 2020, an estimated $123M.
- Iridian Asset Management first reported a position in Medicines Co in Q4 2016 and held it in 13 quarters.
- Iridian Asset Management's Medicines Co position peaked at $150M in Q3 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Iridian Asset Management's 13F filing for Q1 2020, filed 11 May 2020.